<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002635</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000064085</org_study_id>
    <secondary_id>YALE-HIC-7862</secondary_id>
    <secondary_id>NCI-T94-0189D</secondary_id>
    <nct_id>NCT00002635</nct_id>
  </id_info>
  <brief_title>Aminocamptothecin in Treating Patients With T-cell Lymphoma</brief_title>
  <official_title>PHASE II TRIAL OF 9-AMINOCAMPTOTHECIN IN ADVANCED CUTANEOUS T CELL LYMPHOMA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of aminocamptothecin in treating patients&#xD;
      with advanced cutaneous T-cell lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Assess the antitumor activity of aminocamptothecin (9-AC) administered by&#xD;
      72-hour infusion in patients with advanced cutaneous T-cell lymphoma. II. Assess the toxic&#xD;
      effects of 9-AC administered on this schedule.&#xD;
&#xD;
      OUTLINE: Single-Agent Chemotherapy. Aminocamptothecin, 9-AC, NSC-603071.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30 patients will be accrued; if no more than 1 response is seen&#xD;
      in the first 15 patients, the study will close. Probable duration of study is 18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 1995</start_date>
  <completion_date type="Actual">April 2000</completion_date>
  <primary_completion_date type="Actual">April 2000</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">12</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aminocamptothecin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically confirmed, advanced stages IIB/III/IV cutaneous&#xD;
        T-cell lymphoma Measurable or evaluable disease required Measurable disease includes: Skin&#xD;
        disease evaluated by clinical assessment grid method Lesion measurable on imaging (i.e., CT&#xD;
        measurement of lymph nodes) Pure osteolytic lesion Unidimensional lesion for which a normal&#xD;
        measurement is available (e.g., mediastinal width on x-ray) Evaluable disease defined as&#xD;
        malignant disease evident on physical or radiographic exam but not measurable by ruler or&#xD;
        caliper, i.e.: Pelvic masses Confluent multinodular lung metastases Skin metastases CNS&#xD;
        metastases eligible if stable for at least 4 weeks following completion of surgery or&#xD;
        radiotherapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At&#xD;
        least 3 months Hematopoietic: ANC at least 1,500 Platelets at least 100,000 Hepatic:&#xD;
        Bilirubin no greater than 1.5 mg/dL AST less than 3 times normal Renal: Creatinine no&#xD;
        greater than 1.5 mg/dL Other: No contraindication to indwelling central venous catheter No&#xD;
        active infection including HIV No other medical condition that would preclude protocol&#xD;
        compliance No pregnant or nursing women Adequate contraception required of fertile patients&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: Prior biological therapy allowed Chemotherapy:&#xD;
        Prior systemic chemotherapy allowed Patients with more than 1 prior regimen analyzed&#xD;
        separately At least 4 weeks since chemotherapy (6 weeks since nitrosoureas or mitomycin)&#xD;
        Endocrine therapy: Not specified Radiotherapy: Prior skin irradiation allowed At least 4&#xD;
        weeks since wide-field radiotherapy Surgery: Fully recovered from prior surgery Other:&#xD;
        Prior topical therapy allowed Prior PUVA allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John R. Murren, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale Comprehensive Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520-8028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center, Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Medical Center Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2001</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>August 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2004</study_first_posted>
  <last_update_submitted>July 24, 2013</last_update_submitted>
  <last_update_submitted_qc>July 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

